磁共振弹性成像相关肝脏硬度与并发症及死亡率的纵向关联
本回顾性研究纳入2373例慢性肝病患者,每1-6个月评估并发症。多因素分析显示,肝脏硬度每增加1 kPa,肝细胞癌、失代偿和死亡的风险分别显著升高,但与主要不良心血管事件和肝外癌症无显著关联;肝硬化(>4.7 kPa)患者相比轻微纤维化(<3 kPa)患者,肝细胞癌、失代偿和死亡风险显著更高。
要点
- 肝脏硬度每增加1 kPa,肝细胞癌aHR 1.28(95%CI 1.2-1.4)、失代偿aHR 1.34(95%CI 1.3-1.4)、死亡aHR 1.17(95%CI 1.1-1.2)。
- 肝硬化(>4.7 kPa)相比轻微纤维化(<3 kPa),肝细胞癌aHR 4.20(95%CI 2.2-8.2)、失代偿aHR 67.5(95%CI 9.2-492)、死亡aHR 2.90(95%CI 1.6-5.4)。
- 肝脏硬度与主要不良心血管事件和肝外癌症无显著关联,其aHR分别为0.96(95%CI 0.9-1.1)和1.00(95%CI 0.9-1.1)。
核心结论
- 磁共振弹性成像相关肝脏硬度升高与肝细胞癌、失代偿和死亡风险增加呈剂量依赖关联,但与主要不良心血管事件或肝外癌症无显著关联。
- 作者认为磁共振弹性成像在肝脏相关事件和死亡中具有重要作用,但需进一步研究探讨其在主要不良心血管事件和肝外癌症中的作用。
研究设计与样本
- 回顾性研究,纳入2373例连续慢性肝病患者,所有患者接受标准治疗,每1-6个月评估并发症发生情况。
主要发现
- 新诊断肝细胞癌、失代偿、主要不良心血管事件、肝外癌症和死亡分别见于99、117、73、77和170例患者。
- 肝脏硬度每增加1 kPa,肝细胞癌aHR 1.28(95%CI 1.2-1.4)、失代偿aHR 1.34(95%CI 1.3-1.4)、主要不良心血管事件aHR 0.96(95%CI 0.9-1.1)、肝外癌症aHR 1.00(95%CI 0.9-1.1)、死亡aHR 1.17(95%CI 1.1-1.2)。
- 肝硬化(>4.7 kPa)患者相比轻微纤维化(<3 kPa)患者,肝细胞癌aHR 4.20(95%CI 2.2-8.2)、失代偿aHR 67.5(95%CI 9.2-492)、主要不良心血管事件aHR 0.83(95%CI 0.4-1.7)、肝外癌症aHR 0.90(95%CI 0.5-1.7)、死亡aHR 2.90(95%CI 1.6-5.4)。
局限性
- 原文指出需进一步研究探讨磁共振弹性成像在主要不良心血管事件和肝外癌症中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance elastography (MRE) has the highest diagnostic accuracy for liver fibrosis; however, the association between MRE-associated liver stiffness and the development of hepatic and extrahepatic complications as well as mortality remains unclear. AIM: In this study, we investigated the longitudinal association between MRE-associated liver stiffness and complications and mortality. METHODS: This retrospective study included 2373 consecutive patients with chronic liver disease. All patients received standard of care and the development of complications was assessed every 1-6 months. RESULTS: Newly diagnosed hepatocellular carcinoma (HCC), decompensation, major adverse cardiovascular events (MACE), extrahepatic cancer and death were observed in 99, 117, 73, 77 and 170 patients respectively. In multivariable analysis, the adjusted hazard ratios (aHR) (95% confidence interval [CI]) for HCC, decompensation, MACE, extrahepatic cancer and mortality were 1.28 (1.2-1.4), 1.34 (1.3-1.4), 0.96 (0.9-1.1), 1.00 (0.9-1.1) and 1.17 (1.1-1.2), respectively, with each 1-kPa increase in liver stiffness. Similarly, the aHR (95% CI) for HCC, decompensation, MACE, extrahepatic cancer and mortality were 4.20 (2.2-8.2), 67.5 (9.2-492), 0.83 (0.4-1.7), 0.90 (0.5-1.7) and 2.90 (1.6-5.4), respectively, in patients with cirrhosis (>4.7 kPa) compared to those with minimal fibrosis (<3 kPa). CONCLUSIONS: Increased MRE-associated liver stiffness was associated with increased risk for HCC, decompensation and mortality in a dose-dependent fashion but not with MACE or extrahepatic cancer, implicating a significant role for MRE in liver-related events and mortality; however, further studies are warranted to explore its role in MACE and extrahepatic cancer.
引用
- Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther. 2021. PMID: 34927277. doi:10.1111/apt.16745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。